Abstract-Chronic treatment of saline-drmkmg stroke-prone spontaneously hypertensive rats (SHRSP) with agents that interfere with the formation or actions of angotensm II (Ang II) prevents the development of stroke and renal vascular damage Ang II, m addltlon to its direct vascular effects, stimulates the synthesis and release of aldosterone
Abstract-Chronic treatment of saline-drmkmg stroke-prone spontaneously hypertensive rats (SHRSP) with agents that interfere with the formation or actions of angotensm II (Ang II) prevents the development of stroke and renal vascular damage Ang II, m addltlon to its direct vascular effects, stimulates the synthesis and release of aldosterone
To assess the role of aldosterone m the development of pathologc changes m these rats, we implanted time-release pellets containing 200 mg of the mmeralocortlcold receptor antagomst, spu-onolactone, mto 14 SHRSP at 7 5 weeks of age Eight SHRSP httermates received placebo pellets Over the period of study (3 to 4 weeks), systolic blood pressure (SBP) was not different between the groups. Splronolactone did not enhance water and electrolyte excretion All placebo-treated SHRSP developed marked protemuna (150t6 mg/d) whereas m spu-onolactone-treated SHRSP, urinary protein excretion (UPE) averaged 3929 mg/d (P< 0001) In a second study to assess effects on survival, 6 SHRSP received splronolactone (10 mg/kg/d) and 6 received vehicle All but one of the control rats displayed signs of stroke and died by 16 weeks of age, while the splronolactone-treated SHRSP remamed asymptomatlc through 19 weeks of age (P< 03). At 16 weeks of age, splronolactone-treated SHRSP were severely hypertensive (247-+3 mm Hg), yet UPE remained at baseline levels In contrast, pretermmal UPE averaged 136-t 13 mg/d m control rats (PC 0001). In both studies, hlstopathologic exammatlon revealed a marked protective effect of splronolactone against the development of malignant nephrosclerotlc and cerebrovascular lesions These observations indicate a vascular and end organ protective effect of splronolactone m the absence of lowered blood pressure m salme-drmkmg SHRSP and are consistent with a major role for mmeralocortlcords as hormonal mediators of vascular injury (Hypertension. 1998;31[part 2]:451-458.)
Key Words: hypertension n kidney n malignant nephrosclerosls n splronolactone n stroke I n 1972, cluucal studies by Brunner and coworkers identified plasma rerun acnvlty (PRA) and aldosterone as independent nsk factors for heart attack and stroke ' They found that among the patients who developed strokes and myocardlal mfarctlons, all had normal or high PRA, and aldosterone secretlon Previous studies by our group and others have provided expenmental evidence to support a role for the renm-angotensm-aldosterone system (RAAS) m the development of vascular qury, as angotensm converting enzyme (ACE) mhlbltors2-6 and Ang II receptor antagonlsts7-9 prevented the development of stroke and malignant nephrosclerosls m SHRSP Since these studies were conducted m salt-loaded SHRSP, which respond to these agents with nummal blood pressure lowermg, they provided evidence for a pathophyslolog& role for Ang II m the development of vascular lesions of malignant nephrosclerosls independent of severely elevated blood pressure Consistent with a role for Ang II was the finding that SHRSP display a paradoxical increase m PRA with rime, despite continued salt-loading 3 9,'" Although Ang II stimulates the synthesis and release of aldosterone," " m addmon to its direct vascular actions, a role for mmeralocortlcolds m the pathology of SHRSP at 5 to 7 levels and exammed for gross abnormahtles Bram slices were then embedded m paraffin blocks and hlstologlc sections (5 to 7 pm) from each were stained with hematoxyhn and eosm (H & E) and exammed for lesions by hght microscopy wlthout knowledge of the treatment as described previously * Cerebrovascular damage was evaluated usmg a grading system of 0 to 4, based on the extent and dlstrlbutlon of the lesions, without regard for the type or age of the lesion A score of 4 indicated extensive lesions mvolvmg large areas at 3 or more levels, a score of 3 indicated large lesions at 2 levels or small lesions at 3 or more levels, a score of 2 indicated small lesions at 2 or more levels, a score of 1 mdlcated a single damaged area and a score of 0 was assigned when no abnormahtles were observed Kidneys were preserved m 10% phosphate-buffered formahn Coronal sectlons of kidney were cut at 3 to 4 mm, and at least 3 to 4 such blocks were sampled and embedded m paraffin Hlstologc sections (2-3 pm) were stained with H & E and exammed by hght nucroscopy at 20x and 40x m a blinded fashion for lesions, as previously described Results SHRSP from both groups showed a progressive increase m SBP with age ( Fig 1A) By the end of the study, animals m both groups were severely hypertensive No slgmficant dlfferences m SBP were observed between the group? Likewise, heart rate was unchanged by chronic treatment with splronolactone and showed little change over the course of the study (data not shown) There was no difference m UPE between the groups through 9 weeks of age ( Fig 1B) Thereafter, UPE Increased markedly m SHRSP receiving placebo and averaged 15026 mg/d at 10 4 weeks ofage In contrast, UPE remained at low levels and averaged 2225 mg/d at 10 4 weeks of age m the splronolactone-treated group (P< 0001) All animals were sacrificed m the ensuing week Pretermmal UPE averaged 3929 mg/d m the splronolactone-treated ammals Body weight (Fig 1C) increased progressively m both groups through 9 5 weeks of age at which time the weight of placebo-treated animals began to decline Fig 2 shows excretion After placement of the animals on high salt/strokeprone diet, unne volume and sodium excretion increased markedly (PC 0001) whereas potassium excretion remained unchanged The urinary Na+/K+ ratio increased from 0 5120 02 to 5 9720 24 (P< 0001) Urine volume, sodium excretion, and the urinary Na+/K+ ratio were comparable m both the splronolactone-and placebo-treated groups until 10 3 weeks of age, at which time urine output, sodium excretion, and the urinary Na+/K+ ratio were greater m the placebotreated group Urinary potassium excretion was not different between the groups during the study penod There were no slgmficant differences m heart weight (1 420 05 versus 1 52tO 06 g), total kidney weight (2 5650 14 versus 2 5520 06 g), total adrenal weight (64 2-t-5 versus 57 6?5 2 mg) and brain weight (2 05+0 05 versus 2 Ok-10 04 g) between placebo-and splronolactone-treated SHRSP, respectively The Time-release pellets containing either spironolactone (200 mg, 13 to 17 mg/kg/day) or placebo were Implanted subcutaneously at the nape of the neck in 7 5-week-old stroke-prone spontaneously hypertensive rats All animals were then maintained on a 1% NaCl drinking solution and Stroke-Prone Rodent Diet and sacrifled 3 to 4 weeks later *PC 01, tP< 001 compared with placebo Values are mean?SE and rarefaction, sponglosu, hqmfactlve necrosis, and hemorrhage Brains from splronolactone-treated animals showed occasional lesions that were not as marked as m the placebotreated group Representative photonucrographs of renal cortex from SHRSP given either a placebo pellet or a time-release pellet contammg splronolactone are shown m Figs 3A, and 3B, respectively Promment glomerular and vascular lesions of thrombotlc mlcroanglopathy charactenstlc of malignant nephrosclerosls were noted m placebo-treated SHRSP Vascular lesions were pnmanly confined to renal cortex and affected medium-sized to small mterlobular arteries as well as artenoles Vascular lesions consisted predommandy of the thrombotlc type Prohferatlve lesions were noted m lesser numbers The remaining vessels without lesions frequently showed medial thickening Rarely, an arcuate size artery revealed focal fibrmold necrosis Glomeruh revealed predominantly lschemlc retraction of capillary tufts with or without mesangolysls These were probably secondary to preglomerular vascular occlusion A few additional glomeruh were markedly swollen and showed thrombotic lesions In contrast to these changes m placebotreated SHRSP, splronolactone-treated SHRSP exhibited a marked reduction m both renal vascular and glomerular lesions (Table) No appreciable leukocytlc infiltrate was observed m the kidneys of either group PRA averaged 52215 ng Ang I/mL/h m placebo-treated SHRSP, which 1s consistent with the paradoxical increases that are known to occur m salt-loaded SHRSP PRA averaged 16-1-2 ng Ang I/mL/h m the splronolactone-treated SHRSP, which, although elevated, was srgmficant less than m their placebo-treated httermates (P< 01) Protocol 2 In a separate expenmental senes, SHRSP were started on Stroke-Prone Rodent Diet and 1% NaCl dnnkmg solution at 8 8 weeks of age and were chronically treated with either splronolactone (n=6) or vehicle (n=6) Fig 4A shows the cumulative percentage of splronolactoneand vehicle-treated animals survlvmg at &fferent ages Five out of the 6 SHRSP from the vehicle-treated group displayed signs of stroke begmmng at 13 4 weeks of age and died before 16 weeks of age In contrast, none of the splronolactone-treated SHRSP showed stroke signs and all survived until 19 weeks of age at which point the study was ended Mlcroscoplc exammatlon revealed cerebrovascular lesions m the brains of all vehlcletreated SHRSP, commensurate with the demonstration of stroke signs m these animals Brains from splronolactonetreated animals showed occasional lesions of rarefactlon and edema that were not as marked as m the controls The average cerebrovascular lesion score m splronolactone-treated animals was significantly less than m the control group (0 8 t0 6 versus 2 520 5, P< 05) There was no significant difference m systohc blood pressure between the groups over the course of the study (Fig 4B) At 15 weeks of age, splronolactone-treated SHRSP developed severe hypertension, averagmg levels of 259?5 mm Hg Saline intake and urine volume tended to increase with time while food intake and body weight tended to decrease, however, there were no statistically slgmficant differences between the groups (data not shown) Pretermmal UPE m these ammals reached 1362 13 mg/d while levels m splronolactone-treated animals remained at basal levels (1724 mg/d, P< 001 The occurrence of renal vascular and glomerular lesions was also markedly reduced m the kidneys of those SHRSP that were chronically treated with splronolactone The percentage of lesloned glomeruh was 2122 m the vehicle group and 6+4 m the group treated with splronolactone, P< 01 The number of vascular profiles with lesions per 100 glomeruh counted was 28 +4 m the vehicle group and 6t4 m the group treated with splronolactone, P< 01
Discussion
To determine whether endogenous mmeralocortlcolds play a role m the malignant nephrosclerosls and stroke that develops m saline-dnnkmg SHRSP, we chronically administered a mmeralocortlcold receptor antagonist to these animals We found that a low dose of splronolactone, 10 mg/kg/d, markedly increased the survival of sahne-dnnkmg SHRSP as compared to the vehicle-treated group In this expenment, mortality from stroke m the vehicle group also occurred at a somewhat later age relative to that seen m our previous studies This delay 1s best explained by the fact that these animals were started on the high-salt/stroke-prone rodent diet at a later age *' In a separate expenmental senes, we started the animals on high-salt/stroke-prone rodent diet at the usual time Survival was not an endpoint m this study, nonetheless, 3 of the placebo-treated rats developed neurolog& signs of stroke and &ed early Hlstopathologc analysis of the brains from both of these expenments demonstrated a slgmficant reduction m cerebrovascular damage m those SHRSP given splronolactone Previous studies by RobertI demonstrated that rats gven DOCA and a 1% NaCl dnnkmg solution developed neurologcal signs of stroke and cerebrovascular lesions Recent studies by McLeod et al have demonstrated that chronic mfuslon of aldosterone can reverse the ability of captopnl to prevent mortality and cerebrovascular injury m salt-loaded absence of a blood pressure lowermg effect m saline-drmkmg SHRSP Chronic ACE inhibitor treatment with enalapnl also failed to lower arterial pressure m rats with DOCA-salt hypertension but, m contrast to SHRSP, did not protect against the development of protemuna and mahgnant nephrosclerosls 23 Aldosterone has also been reported to play a role m the development of renal qury m the remnant kidney model of chronic renal failure 24 In that study, exogenous aldosterone admmlstratlon completely reversed the ablhty of combined treatment with enalapnl and losartan to attenuate protemuna, hypertension, and glomerular sclerosis Although the ultimate development of glomerular sclerosis was not prevented, chronic admmlstratlon of a high dose of splronolactone significantly delayed the development of protemuna m the remnant kidney model of renal failure In a recent study we also found that aldosterone mfuslon can completely reverse the renal protective action of captopnl m saline-drmkmg SHRSP 25 The findings m the present study with splronolactone provide strong evidence for a nqor role of endogenous mmeralocortlcolds m the development of renal vascular pathology of saline-dnnkmg SHRSP A relatlonshlp between mmeralocortlcolds and malignant nephrosclerosls m rats was first demonstrated by Selye and coworkers m 1943 " They reported that combined treatment with DOCA and a 1% NaCl-drmkmg solution produced severe hypertension and malignant nephrosclerosls while DOCA was comparatively mactlve when NaCl intake was not excessive The contnbutlon of mmeralocortlcolds to vascular injury may have baen particularly prominent under the condltlons of our study, since SHRSP were mamtamed on a 1% NaCl-drmkmg solution In the present study PRA was markedly elevated m placebotreated SHRSP, which 1s consistent with the paradoxJca1 increase known to occur with salt-loading m these ahlmals 3.1032 PRA averaged 16 0+2 0 ng Ang I/mL/h m splronolactone-treated SHRSP Although this value was less than m placebo-treated SHRSP, it was substantially elevated compared to our previously reported values of 3 5t 1 0 ng Ang I/mL/h m WKY gven standard diet and water, 0 620 3 ng Ang I/mL/h m WKY given Stroke-Prone Rodent Diet and 1% NaCl, and 9 22-2 5 ng Ang I/mL/h m SHRSP given standard diet and water " The higher level of PRA m placebo-treated SHRSP relative to that of splronolactonetreated SHRSP 1s probably due to the extensive renal damage that was observed m the former group (Table) Consistent with the concept that the protective effect of splronolactone relates to mmeralocortlcold receptor antagonism rather than effects on PRA 1s the findmg that aldosterone can restore the development of cerebral** and renal" vascular qury m saltloaded SHRSP chronically treated with the ACE mhlbltor captopnl
The protective effect of splronolactone treatment against end organ damage m SHRSP appears to be independent of blood pressure lowermg, since limited, if any, reduction m blood pressure was observed m either of the study protocols Although m some Instances blood pressure tended to be lower m splronolactone-treated rats, this may reflect the decreased renal vascular damage m this group These observations are similar to the finding that ACE mhlbltors afford vascular protection m saline-dnnkmg SHRSP with little or no reductlon m systemic blood pressure *M In salt-loaded rats recelvmg a penpheral mfuslon of aldosterone, concomitant mtracerebroventricular mfuslon of a mmeralocortlcold receptor antagonist, RU28318, abohshed aldosterone-mduced hypertension but did not affect the production of cardiac hypertrophy or fibrosis " These findmgs provide evidence for a central nervous system component to the hypertensive effect of aldosterone as previously described by Gomez-Sanchez" *' and also support a dlssoclatlon between blood pressure and end organ damage
The beneficial effects of splronolactone m saline-dnnkmg SHRSP were also independent of major changes m water and electrolyte excretion Chronic admmlstratlon of mild diuretics 1s typically associated with only a transient increase m water and electrolyte excretion that IS not sustained In rats on a normal sodium intake, admmlstratlon of splronolactone at a dose of 20 mg/kg/d for one week did not alter dally unnary potassium excretion 29 Increases m urmary sodium excretion (10%) and the urmary Na+/K+ ratio (15%) were observed only on the first day of treatment 29 We observed no differences m water and electrolyte excretion between the groups until the onset of renal damage, signified by protemuna, at which time unne output and sodium excretion were higher m placebotreated rats Smeda and Tkachenko3" exammed the effects of various diuretics on survival of salt-loaded SHRSP They found that chronic treatment with chlorothlazlde or amllonde offered no protection against stroke and concluded that mcreases or decreases m unnary potassium excretion do not affect the development of pathology m these ammals Also m this study, furosemlde treatment decreased survival of SHRSP, which was thought to be caused by actlvatlon of the P.AAS Previous stu&es have demonstrated a protective effect of high dietary potassmm agamst the development of stroke m SHRSP,3' " which was not associated with increases m plasma potassium levels 33 Thus, mcreases m serum potassium, per se, may not play a maJor role m the vascular protective effect of high dietary potassium m salt-loaded SHRSP 33 Studies by Volpe and coworkers3* demonstrated that the protective effect of high dietary potassium m salt-loaded SHRSP was most likely due to suppression of remn release and not dmresls and natnuresls Likewise, we found that chronic treatment with enalapnl or captoprll had no effect on water and electrolyte excretion by saline-drmkmg SHRSP but prevented end organ damage Our results with splronolactone are commensurate with these findings and support the concept that the protective effect with this treatment 1s not due to major changes m water and electrolyte excretion
The precise mechanism by which mmeralocortlcolds contnbute to the development of vascular pathology m salmednnkmg SHRSP remains unclear Chrome treatment with splronolactone has been reported to prevent myocardlal fibrosis m rats with hypertension induced by unilateral renal lschenuaz"~34*3s or chronic aldosterone mfuslon 34 It has been suggested that these pathophyslologc effects of aldosterone occur via nonepithehal mmeralocortlcold receptors, have a time course of days to weeks rather than hours, reflect occupancy of only a small percentage of such receptors, and reqmre salt loading " It also has been suggested that aldosterone may alter myocardlal permeablhty so that fibrosis might be a secondary event accompanymg the appearance of growth factors 36 The posslblhty that aldosterone exerts smular mfluences m other tissues and organs cannot be excluded and should be further mvestlgated Aldosterone and Ang II were found to increase protem kmase C actlvlty m vascular smooth muscle cell?' and protein kmase C actlvatlon has been reported to increase vascular permeability 3*,3y Ulhan and coworkers"" demonstrated a direct relationship between the activity of aldosterone and Ang II m vascular smooth muscle cells They found that aldosterone upregulates Ang II membrane receptors, thereby increasing the synthesis of montol-1,4,5-tnphosphate and release of intracellular Ca++ This upregulatlon was inhibited to a considerable extent by splronolactone, suggestmg that it was pnmanly mediated by the mmeralocortlcold receptor These findings are consistent with a synergstlc interaction between Ang II and aldosterone m the production of vascular pathology, which was first proposed by Masson and coworkers 41 Thus, an interaction between Ang II and aldosterone may be Important m the production of end-organ damage m SHRSP In summary, chronic treatment with the mmeralocortlcold receptor antagonist, splronolactone, markedly dlmmlshed protemuna, renal lesions of malignant nephrosclerosls and signs of stroke m saline-drmkmg SHRSP Spironolactone treatment m these animals had little or no effect on systolic artenal blood pressure or water and electrolyte excretion These results suggest that aldosterone, or a related factor with mmeralocortlcold activity, plays a major role m the development of vascular Injury m sahne-drmkmg SHRSP
